Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
6,624.70
(
-1.36%
)
US TECH 100
23,755.20
(
-1.56%
)
Dow Jones
46,225.15
(
-1.63%
)
Brent Oil
107.76
(
1.11%
)
Bitcoin
71,459.32
(
0.30%
)
News Focus
News Focus
Post# of 257257
Next 10
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

DewDiligence

Send PM Follow Ignore
Followers 842
Posts 122795
Boards Moderated 10
Alias Born 09/05/2002

DewDiligence

Member Level

Re: dewophile post# 41494

Friday, 02/02/2007 12:29:54 PM

Friday, February 02, 2007 12:29:54 PM

Post# of 257257
> vrtx will have plenty of naive trial data that is not tainted by more than one investigational compound<

Not sure I agree here.

If there were a safety problem in a combination trial with VX-950 in the treatment-refractory setting, why do you assume that there would be no taint to affect VX-950 development in the treatment-naïve setting? Even the ~1,000 patients that will have been tested in the treatment-naïve setting are not a lot of patients when it comes to detecting rare side effects.

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

Trade Smarter with Thousands

Leverage decades of market experience shared openly.

Join Now